Menu:

-What causes TTP-HUS?

-What is the treatment for TTP-HUS?

-What is the outcome for TTP-HUS?

-What is the future for patients who recover from TTP-HUS?

-What research is being done on TTP-HUS in Oklahoma?

-How can I learn more about TTP-HUS?

 

 

WHAT IS THE FREQUENCY OF TTP-HUS?

We see all of the patients with TTP-HUS in Central and Western Oklahoma because the Oklahoma Blood Institute (OBI) does all of the plasma exchange treatments in our region. During the past 19 years we have treated 381 patients. We treat about 20 patients each year in all hospitals in Oklahoma City, Midwest City, Norman, and Edmond.

Because we see all patients who are diagnosed with TTP or HUS in a defined region of Oklahoma, we can estimate how often TTP-HUS occurs. Since we know this for our region of Oklahoma, we can use U.S. census data to compare our region to the U.S. population, so we can also estimate how often TTP-HUS occurs in the U.S. Our estimate for all patients who are diagnosed with TTP or HUS and treated with plasma exchange in the U.S. is 11 people per 1,000,000 people per year. For the patients who have a deficiency of ADAMTS13, an enzyme described below, the estimate is 2 people per 1,000,000 people per year. TTP-HUS occurs more commonly in women than in men. It can occur at any age, but it is rare in children. Among patients with ADAMTS13 deficiency, it is more common among black Americans.

Click the following links for more details about

What causes TTP-HUS?

What is the treatment for TTP-HUS?

What is the outcome for TTP-HUS?

What is the future for patients who recover from TTP-HUS?

What research is being done on TTP-HUS in Oklahoma?

How can I learn more about TTP-HUS?

IMPORTANT!

The information included in this website is for educational purposes only. The designers and operators of this site take no responsibility for the things you may do with this information. For advice on your unique medical condition, please consult your health care professional. By going further into this website you acknowledge that you have read and understood this disclaimer.